RC
ABBV icon

Rexford Capital’s AbbVie ABBV Stock Holding History

Rexford Capital’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$798K Buy
3,172
+924
+41% +$199K 0.49% 59
2026
Q1 		$489K Buy
2,248
+33
+1% +$7.32K 0.35% 84
2025
Q4 		$506K Hold
2,215
– – 0.38% 82
2025
Q3 		$513K Hold
2,215
– – 0.4% 79
2025
Q2 		$411K Buy
+2,215
New +$412K 0.34% 95

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Rexford Capital's ABBV Position: Q2 2026 in Review

Rexford Capital increased its AbbVie (ABBV) stake by 41% in Q2 2026, buying an estimated $199K and bringing the position to 3,172 shares worth $798K. The position accounts for 0.49% of the portfolio, ranked #59.

Rexford Capital first reported a position in ABBV in Q2 2025 and has held it in 5 quarters since. 4,234 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Rexford Capital held 3,172 shares of AbbVie worth $798K as of Q2 2026.
  • Rexford Capital bought 924 AbbVie shares in Q2 2026, an estimated $199K.
  • AbbVie made up 0.49% of Rexford Capital's portfolio in Q2 2026, its #59 holding.
  • Rexford Capital first reported a position in AbbVie in Q2 2025 and has held it in 5 quarters since.
  • 4,234 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Rexford Capital's 13F filing for Q2 2026, filed 29 Jul 2026.